Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI133
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI133 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 3 (HER3; also known as ErbB3), conjugated to a topoisomerase I inhibitor payload. The drug is designed for antineoplastic activity by specifically binding to HER3-expressing tumor cells and delivering the cytotoxic topoisomerase I inhibitor directly to these cells, thereby inhibiting their proliferation and inducing cell death. It is being developed primarily for the treatment of solid tumors, including advanced, unresectable, or metastatic malignant solid neoplasms. The developer and manufacturer is Innovent Biologics.
- Other names
- anti-HER3/topoisomerase I inhibitor antibody-drug conjugate
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on IBI133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI133.